14.2 Heart Failure Phenotype, Acuity, and Hypertensive Combinations

Heart failure: phenotype, acuity, and associated conditions

Heart-failure review begins with the clinician's diagnosis and the patient's course. Keep three questions separate: what heart-failure phenotype is documented, whether an acute component is present, and which associated-condition instructions apply. An ejection fraction, natriuretic peptide, or diuretic order contributes evidence but does not independently answer all three questions.

The purpose of clarification is an accurate description of illness. “CHF” remains a recognized Index term; it is not prohibited or automatically false. Greater specificity can improve the record when supported, but a query must permit the provider to reach the clinically appropriate conclusion, including uncertainty.

Clinical EF categories are not the whole diagnosis

The 2022 AHA/ACC/HFSA guideline's official slide set distinguishes these clinical categories:

Evidence of increased filling pressures can be spontaneous or provoked and may involve natriuretic peptides, imaging, or invasive measurements. A normal-range EF alone does not establish HFpEF; conversely, it does not exclude heart failure. The clinical history, symptoms, examination, and further assessment matter.

EF category also does not determine acuity. A patient with chronically reduced EF can be stable, and a patient with preserved EF can develop acute decompensation. A follow-up EF above 40% after prior HFrEF should not automatically be relabeled new diastolic failure merely because the number improved. Ask about the intended diagnosis when the documentation and history leave a meaningful ambiguity.

The Index recognizes HF with reduced EF under the systolic pathway and HF with preserved or normal EF under the diastolic pathway. These are documented diagnostic terms; CDI need not require a second synonym simply to duplicate an already clear diagnosis. Clinical terms such as HFmrEF or HFimpEF require attention to the complete provider description and applicable Index path rather than a reviewer converting a percentage into systolic, diastolic, or combined failure.

Combined systolic and diastolic failure is also a recognized category. The FY 2027 Tabular List includes heart failure with reduced EF and diastolic dysfunction under I50.4-. Check the actual diagnostic wording and Index route; do not independently construct combined heart failure from an echo's numerical or descriptive findings alone.

Establish the acute component from the course

Review the baseline symptoms and function, the reason for presentation, evidence of congestion or impaired perfusion, actual interventions, and the provider's assessment. Findings such as new orthopnea, pulmonary congestion, edema, weight change, or worsening function can support evaluation. They do not all have to appear in every case, and each has alternative explanations.

Compare the admission course with the established baseline. “Acute” and “acute on chronic” are not interchangeable. An old HF diagnosis, current treatment, and a new symptom do not authorize the reviewer to choose an acuity without interpreting the actual documented assessment.

The Index contains additional instructions for decompensated HF. For example, the heart-failure entry directs decompensated systolic and diastolic terms to their acute-and-chronic pathways; unqualified heart failure with decompensation remains I50.9 in that entry. Do not impose a universal rule that every use of “decompensated” means only acute HF, or that it supplies a missing systolic/diastolic subtype. Follow the full documented phrase and clarify genuine inconsistency.

Use biomarkers and treatment as evidence

BNP or NT-proBNP can support diagnostic evaluation. The AHA guideline also lists other reasons for elevated values, including atrial fibrillation, advancing age, renal failure, pulmonary embolism, and critical illness. The ACC's 2023 HFpEF consensus notes that natriuretic peptide levels can be lower in obesity. An isolated high value therefore does not prove acute HF, while a relatively low value does not settle every HFpEF assessment.

Imaging may show congestion or structural abnormalities, but a pleural effusion or enlarged heart alone does not establish a specific acute phenotype. Preserve the report and the provider's interpretation instead of replacing them with the reviewer's conclusion.

Loop-diuretic administration and response can help explain the clinical course, but treatment is not exclusive to one cause of edema. Check what was actually administered, its indication, and any held or discontinued orders. There is no universal dose, infusion requirement, or peptide cutoff that independently establishes an acute systolic, diastolic, or combined diagnosis for coding.

Apply the actual code and severity distinctions

FY 2027 I50 distinguishes systolic, diastolic, and combined failure, with separate acute, chronic, acute-on-chronic, and unspecified-acuity codes. Final MS-DRG v44 Appendix C identifies these secondary-diagnosis classifications:

Thus, acute diastolic failure is not a CC in this version. Verify the exact code and version instead of assuming every diastolic code has the same status.

I50.9 is heart failure, unspecified, and is not listed as a CC/MCC in Appendix C part 1. That classification does not mean the illness has no clinical significance, no effect in every risk model, or that another severity tier has necessarily been lost. A more specific diagnosis may leave the final DRG unchanged because of exclusions, other diagnoses, or the grouping pathway.

Other types require their own instructions. Right-sided failure has distinct entries; biventricular failure (I50.82) and end-stage failure (I50.84) have code-also instructions for the known type of left-ventricular or heart failure. They are not an interchangeable set of acute/chronic codes. Do not extend the table's severity classifications to every I50 code or count each description as an independent severity increment.

Hypertension and CKD change the code set

Under FY 2027 I.C.9.a, hypertension and qualifying heart disease, including heart failure, are presumed related unless documentation clearly states they are unrelated. Another possible cause, such as ischemic heart disease, does not by itself establish nonrelationship. Do not demand a separate “hypertensive heart failure” sentence when the classification already supplies the relationship.

When applicable, I11.0 identifies hypertensive heart disease with heart failure, with an additional I50.- code to identify the HF type. If hypertension, qualifying heart disease, and CKD are present with the presumed relationships intact, consider I13 instead. Hypertension with CKD alone is a different pathway, generally I12, rather than automatically I13.

• I13.0 describes hypertensive heart and CKD with HF and stage 1–4 or unspecified CKD. Its instructions require additional HF-type and CKD-stage codes.
• I13.2 describes the corresponding combination with stage 5 CKD or ESRD, with the specified additional codes.

These are code-set and relative-sequencing instructions, not a declaration that I13 is principal in every hospitalization involving the kidneys or heart. Apply the circumstances of admission, other applicable sequencing rules, and the complete documented conditions. Acute kidney injury is distinct from the CKD stage and may require its own code when reportable.

Worked coding example

An admission is established after study as chiefly for acute-on-chronic systolic HF. The provider also documents hypertension and stage 3 CKD without further subdivision. No documentation indicates nonrelationship, and no competing principal-diagnosis or special sequencing issue applies. The hypertensive heart/CKD combination is represented by I13.0, with I50.23 and N18.30 as the additional codes identifying HF type/acuity and CKD stage.

The example expressly establishes systolic HF through provider documentation. A record saying only “CHF” with EF 28% does not independently justify inserting I50.23 into the same sequence. Likewise, do not turn stage 3 into 3a or 3b from an isolated laboratory estimate without the required provider diagnosis.

Frame a useful query

For “CHF” with an unclear current phenotype or acuity, present the relevant prior and current assessments, dated testing, symptoms, actual treatment, and competing explanations. Ask about the unresolved element. A fixed menu listing every acute, chronic, and combined variant is not automatically compliant simply because it is long.

Use supported options or an appropriate open-ended format, permit an alternative response, and avoid CC/MCC, reimbursement, or quality-score pressure. A provider may confirm a more specific diagnosis, retain an unspecified description, or identify another cause. Reconcile that response with the record, then apply classification, reportability, and complete grouping separately.

Sources: 2022 AHA/ACC/HFSA official guideline slide set, tables 4 and 6; 2023 ACC HFpEF consensus key points; FY 2027 ICD-10-CM I.C.9.a; FY 2027 Index and Tabular List, Failure/heart and I50/I13; final MS-DRG v44 Appendix C; 2026 query brief.